SG11201508092YA - Gla monotherapy for use in cancer treatment - Google Patents

Gla monotherapy for use in cancer treatment

Info

Publication number
SG11201508092YA
SG11201508092YA SG11201508092YA SG11201508092YA SG11201508092YA SG 11201508092Y A SG11201508092Y A SG 11201508092YA SG 11201508092Y A SG11201508092Y A SG 11201508092YA SG 11201508092Y A SG11201508092Y A SG 11201508092YA SG 11201508092Y A SG11201508092Y A SG 11201508092YA
Authority
SG
Singapore
Prior art keywords
cancer treatment
gla
monotherapy
gla monotherapy
cancer
Prior art date
Application number
SG11201508092YA
Inventor
Cuenca Carlos V Paya
Meulen Jan Henrik Ter
Original Assignee
Immune Design Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Design Corp filed Critical Immune Design Corp
Publication of SG11201508092YA publication Critical patent/SG11201508092YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201508092YA 2013-04-18 2014-04-18 Gla monotherapy for use in cancer treatment SG11201508092YA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361813499P 2013-04-18 2013-04-18
US201361826311P 2013-05-22 2013-05-22
US201361834415P 2013-06-12 2013-06-12
US201361891609P 2013-10-16 2013-10-16
US201461946317P 2014-02-28 2014-02-28
PCT/US2014/034654 WO2014172637A1 (en) 2013-04-18 2014-04-18 Gla monotherapy for use in cancer treatment

Publications (1)

Publication Number Publication Date
SG11201508092YA true SG11201508092YA (en) 2015-10-29

Family

ID=50977054

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201508092YA SG11201508092YA (en) 2013-04-18 2014-04-18 Gla monotherapy for use in cancer treatment

Country Status (14)

Country Link
US (5) US8957047B2 (en)
EP (2) EP2986303B1 (en)
JP (2) JP6426706B2 (en)
KR (1) KR102039520B1 (en)
CN (1) CN105209047B (en)
AU (2) AU2014253791B2 (en)
BR (1) BR112015025709A2 (en)
CA (1) CA2909221A1 (en)
EA (1) EA032326B1 (en)
HK (1) HK1214510A1 (en)
MX (1) MX370573B (en)
SG (1) SG11201508092YA (en)
WO (1) WO2014172637A1 (en)
ZA (2) ZA201507278B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141861A1 (en) * 2009-06-05 2010-12-09 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
AU2014253791B2 (en) * 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) * 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
JP6887378B2 (en) 2014-11-06 2021-06-16 バイオセラ，インク． Beta-glucan methods and compositions that affect the intratumoral microenvironment
EP3307313A1 (en) 2015-06-12 2018-04-18 GlaxoSmithKline Biologicals SA Adenovirus polynucleotides and polypeptides
AU2016304597B2 (en) * 2015-08-06 2022-10-06 Memorial Sloan Kettering Cancer Center Methods and compositions for tumor therapy
BR112018002520A2 (en) * 2015-08-06 2018-09-18 Glaxosmithkline Ip Dev Ltd TLR4 AGONISTS AND COMPOSITIONS OF THE SAME AND ITS USE IN CANCER TREATMENT
ES2839212T3 (en) * 2015-09-29 2021-07-05 Inst Nat Sante Rech Med Methods to determine the metabolic status of B lymphomas
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
WO2018148180A2 (en) * 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
AU2018304530B2 (en) * 2017-07-17 2024-02-15 Centre National De La Recherche Scientifique Injectable water-in-oil emulsions and uses thereof
CN113750239B (en) * 2021-08-18 2022-11-25 江苏省肿瘤医院 Pharmaceutical composition for treating cervical cancer and pharmaceutical preparation and application thereof
KR20240038596A (en) 2022-09-16 2024-03-25 (주)한국원자력 엔지니어링 A composition for preventing or treating cancer, having abscopal effect and a method of preventing or treating cancer using the same

Family Cites Families (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4029762A (en) 1971-11-17 1977-06-14 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Lipid A-preparation
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4420558A (en) 1981-02-12 1983-12-13 Janssen Pharmaceutica N.V. Bright field light microscopic method of enumerating and characterizing subtypes of white blood cells and their precursors
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4436728A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4420461A (en) 1982-05-26 1983-12-13 Ortho Diagnostic Systems Inc. Agglutination-inhibition test kit for detecting immune complexes
US4435386A (en) 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4663306A (en) 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
US4743540A (en) 1983-09-27 1988-05-10 Memorial Sloan-Kettering Cancer Center Method for diagnosis of subclassifications of common varied immunodeficiency disease group
US5147785A (en) 1983-11-01 1992-09-15 Amtl Corporation Method and apparatus for measuring the degree of reaction between a foreign entity and white blood cells
US4614722A (en) 1983-11-01 1986-09-30 Pasula Mark J Method and apparatus for measuring the degree of reaction between antigens and leukocyte cellular antibodies
US4595654A (en) 1983-11-07 1986-06-17 Immunomedics Inc. Method for detecting immune complexes in serum
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4629722A (en) 1984-07-12 1986-12-16 Ribi Immunochem Research, Inc. Method of inhibiting the onset of acute radiation syndrome
US4844894A (en) 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US5612041A (en) 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4659659A (en) 1985-01-22 1987-04-21 Monsanto Company Diagnostic method for diseases having an arthritic component
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
FI861417A0 (en) 1985-04-15 1986-04-01 Endotronics Inc HEPATITIS B YTANTIGEN FRAMSTAELLD MED REKOMBINANT-DNA-TEKNIK, VACCIN, DIAGNOSTISKT MEDEL OCH CELLINJER SAMT FOERFARANDEN FOER FRAMSTAELLNING DAERAV.
US4746742A (en) 1985-11-28 1988-05-24 Toho Yakuhin Kogyo Kabushiki Kaisha Analogs of nonreducing monosaccharide moiety of lipid A
US6514691B1 (en) 1986-01-22 2003-02-04 Institut Pasteur Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2
US5976785A (en) 1986-01-22 1999-11-02 Institut Pasteur Competitive assays for determining the effectiveness of a human immunodeficiency virus type 2 (HIV-2) antiviral agent, employing peptides and proteins of HIV-2
US5310651A (en) 1986-01-22 1994-05-10 Institut Pasteur DNA probes of human immunodeficiency virus type 2 (HIV-2), and methods employing these probes for dectecting the presence of HIV-2
US6054565A (en) 1986-03-03 2000-04-25 Institut Pasteur Nucleic Acids of HIV-2, Diagnostic Test Kit and Method using Nucleic Acid Probes of HIV-2
US5169763A (en) 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
JPH0755906B2 (en) 1986-07-01 1995-06-14 第一製薬株式会社 Analgesic containing disaturated derivative
US4948587A (en) 1986-07-08 1990-08-14 Massachusetts Institute Of Technology Ultrasound enhancement of transbuccal drug delivery
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2672290B1 (en) 1991-02-05 1995-04-21 Pasteur Institut SPECIFIC PEPTIDE SEQUENCES OF THE HEPATIC STAGES OF P. FALCIPARUM CARRIERS OF EPITOPES CAPABLE OF STIMULATING T-LYMPHOCYTES
US5565209A (en) 1987-03-17 1996-10-15 Akzo Nobel N.V. Adjuvant mixture
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
US4780212A (en) 1987-07-31 1988-10-25 Massachusetts Institute Of Technology Ultrasound enchancement of membrane permeability
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
EP0324455A3 (en) 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
GB2232892B (en) 1988-02-23 1991-07-24 John Mark Tucker Occlusive body for administering a physiologically active substance
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5888519A (en) 1988-06-02 1999-03-30 The United States Of America As Represented By The Secretary Of The Army Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE3826572A1 (en) 1988-08-04 1990-02-08 Hoechst Ag METHOD FOR THE PRODUCTION OF HIGHLY PURE 5.5 '- (2,2,2-TRIFLUOR-1- (TRIFLUORMETHYL) -ETHYLIDEN) TO 1,3-ISOBENZOFURANDION, USE OF THE PROCESS PRODUCT FOR THE PRODUCTION OF POLYIMIDES AND THEIR DERIVATIVES
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US5231168A (en) 1988-09-16 1993-07-27 Statens Seruminstitut Malaria antigen
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
JP3237842B2 (en) 1988-12-16 2001-12-10 オランダ国 Pneumolysin mutants and pneumococcal vaccines produced therefrom
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
DK0382271T3 (en) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler as adjuvants in vaccines
FR2649012B1 (en) 1989-07-03 1991-10-25 Seppic Sa INJECTABLE MULTIPHASIC EMULSIONS
FR2649013B1 (en) 1989-07-03 1991-10-25 Seppic Sa VACCINES AND VECTORS OF FLUID ACTIVE INGREDIENTS CONTAINING METABOLIZABLE OIL
EP0414374B1 (en) 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Novel antigens and methods for their preparation
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US4981684A (en) 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US6120769A (en) 1989-11-03 2000-09-19 Immulogic Pharmaceutical Corporation Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US5298396A (en) 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5124141A (en) 1990-06-14 1992-06-23 Flow Incorporated Method for diagnosing malaria
US5162990A (en) 1990-06-15 1992-11-10 The United States Of America As Represented By The United States Navy System and method for quantifying macrophage phagocytosis by computer image analysis
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
DE122007000019I1 (en) 1991-07-19 2007-07-26 Univ Queensland Vaccines against papillomavirus
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
DK0596032T4 (en) 1991-07-25 2004-07-26 Idec Pharma Corp Induction of cytotoxic T lymphocyte responses
AU660325B2 (en) 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5530113A (en) 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
WO1993010152A1 (en) 1991-11-16 1993-05-27 Smithkline Beecham Biologicals S.A. HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG
US6057427A (en) 1991-11-20 2000-05-02 Trustees Of Dartmouth College Antibody to cytokine response gene 2(CR2) polypeptide
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
US5286718A (en) 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
JPH05328975A (en) 1992-06-02 1993-12-14 Takara Shuzo Co Ltd E1a-f gene
JPH07507689A (en) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Specific tissue targeting methods and compositions
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
HU219808B (en) 1992-06-25 2001-08-28 Smithkline Beecham Biologicals S.A. Vaccine composition containing adjuvant and process for preparation thereof
DE122007000095I1 (en) 1992-06-25 2008-03-27 PAPILLOMA VIRUS VACCINE
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5411865A (en) 1993-01-15 1995-05-02 Iasys Corporation Method of detecting anti-leishmania parasite antibodies
ATE296111T1 (en) 1993-03-09 2005-06-15 Univ Rochester PRODUCTION OF HUMAN PAPILLOMA VIRUS ENCLOSURE PROTEIN AND VIRUS-LIKE PARTICLES
DE69405551T3 (en) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-DEAZYLATED MONOPHOSPHORYL LIPID A-CONTAINING VACCINE COMPOSITIONS
US5532133A (en) 1993-06-02 1996-07-02 New York University Plasmodium vivax blood stage antigens, PvESP-1, antibodies, and diagnostic assays
JP3286030B2 (en) 1993-08-10 2002-05-27 株式会社東芝 Maintenance management device and maintenance management guide device
US6106824A (en) 1993-08-13 2000-08-22 The Rockefeller University Expression of growth associated protein B-50/GAP-43 in vitro and in vivo
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
EP0887867B1 (en) 1993-11-02 2004-04-21 Matsushita Electric Industrial Co., Ltd Semiconductor device comprising an aggregate of semiconductor micro-needles
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5458140A (en) 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US6005099A (en) 1993-11-17 1999-12-21 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5591139A (en) 1994-06-06 1997-01-07 The Regents Of The University Of California IC-processed microneedles
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US7037712B2 (en) 1994-07-26 2006-05-02 Commonwealth Scientific And Industrial Research Organisation DNA encoding ovine adenovirus (OAV287) and its use as a viral vector
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
SE9403137D0 (en) 1994-09-20 1994-09-20 Perstorp Ab Derivatives of carbohydrates and compositions containing them
WO1996011272A2 (en) 1994-10-07 1996-04-18 Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh Papilloma virus-like particles, fusion proteins and process for producing the same
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2727689A1 (en) 1994-12-01 1996-06-07 Transgene Sa NEW PROCESS FOR THE PREPARATION OF A VIRAL VECTOR
EP1484067A3 (en) 1995-02-08 2005-03-02 Takara Bio Inc. Cancer control
WO1996026277A1 (en) 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5912166A (en) 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5718904A (en) 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5993800A (en) 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US6309847B1 (en) 1995-07-05 2001-10-30 Yeda Research And Development Co. Ltd. Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
AU7254396A (en) 1995-09-29 1997-04-17 Eisai Research Institute Method for treating alcoholic liver disease
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5618275A (en) 1995-10-27 1997-04-08 Sonex International Corporation Ultrasonic method and apparatus for cosmetic and dermatological applications
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
US5846758A (en) 1995-11-30 1998-12-08 His Excellency Ghassan I. Shaker Method for diagnosing autoimmune diseases
SE9600648D0 (en) 1996-02-21 1996-02-21 Bror Morein Receptor binding unit
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US5762943A (en) 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
DK0909562T3 (en) 1996-07-03 2005-08-22 Eisai Co Ltd Injection preparation containing a lipid A analog and process for its preparation
CA2265889A1 (en) 1996-09-06 1998-03-12 The Regents Of The University Of California E25a protein, methods for production and use thereof
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
ATE292980T1 (en) 1996-10-11 2005-04-15 Univ California IMMUNO-STIMULATING OLIGONUCLEOTIDE CONJUGATES
JPH10131046A (en) 1996-10-29 1998-05-19 Nikka Chem Co Ltd Durable ph-buffering processing of fiber
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
DE19654221B4 (en) 1996-12-23 2005-11-24 Telefonaktiebolaget Lm Ericsson (Publ) Line connection circuit
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
JP3844366B2 (en) 1997-02-25 2006-11-08 コリクサ コーポレイション Compounds for immunodiagnosis of prostate cancer and methods for their use
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
KR100603884B1 (en) 1997-04-01 2006-07-24 코리사 코퍼레이션 Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
US6358508B1 (en) 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
WO1998058956A2 (en) 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Methods for inducing an immune response involving prime-boost protocols
KR100619350B1 (en) 1997-07-21 2006-09-05 박스터 헬쓰케어 에스.에이. Modified immunogenic pneumolysin compositions as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6749856B1 (en) 1997-09-11 2004-06-15 The United States Of America, As Represented By The Department Of Health And Human Services Mucosal cytotoxic T lymphocyte responses
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
BR9814912A (en) 1997-11-28 2000-10-03 Genset Sa Genetic sequence and polypeptides of chlamydia trachomatis, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
US7012134B2 (en) 1998-01-26 2006-03-14 Human Genome Sciences, Inc. Dendritic enriched secreted lymphocyte activation molecule
DE19803453A1 (en) 1998-01-30 1999-08-12 Boehringer Ingelheim Int vaccine
JP4768121B2 (en) 1998-02-05 2011-09-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Tumor associated antigens from the MAGE family and the nucleic acid sequences encoding them, the use of fusion proteins and for the preparation of compositions for vaccination
DE69919984T2 (en) 1998-02-12 2005-11-17 Wyeth Holdings Corp. INTERLEUKIN-12 AND HERPES SIMPLEX VIRUSANTIGEN CONTAINING VACCINES
DE59913841D1 (en) 1998-02-12 2006-10-26 Infineon Technologies Ag EEPROM and method for driving an EEPROM
US6596501B2 (en) 1998-02-23 2003-07-22 Fred Hutchinson Cancer Research Center Method of diagnosing autoimmune disease
FR2775601B1 (en) 1998-03-03 2001-09-21 Merial Sas RECOMBINANT LIVING VACCINES AND ADJUVANTS
BR9908599A (en) 1998-03-09 2000-11-14 Smithkline Beecham Biolog Combined vaccine compositions
AU753995B2 (en) 1998-04-07 2002-10-31 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
GB2336310B (en) 1998-04-14 2003-09-10 Stowic Resources Ltd Method of manufacturing transdermal patches
EP1073734B1 (en) 1998-04-15 2009-09-23 Ludwig Institute for Cancer Research Ltd. Tumor associated nucleic acids and uses therefor
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
BR9910269A (en) 1998-05-07 2001-01-09 Corixa Corp Adjuvant composition and methods for its use
US6322532B1 (en) 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
KR20070112860A (en) 1998-07-14 2007-11-27 코릭사 코포레이션 An isolated immnogenic portion of the prostate tumor protein and methods for diagnosis of prostate cancer using the same
US6828155B1 (en) 1998-09-01 2004-12-07 Eisai Co., Ltd. Method for evaluating lipid a analog-containing injections
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US6375944B1 (en) 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
WO2000018929A2 (en) 1998-09-25 2000-04-06 Smithkline Beecham Biologicals S.A. Paramyxovirus vaccines
US7001770B1 (en) 1998-10-15 2006-02-21 Canji, Inc. Calpain inhibitors and their applications
DE122007000087I1 (en) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa ADJUVANCY SYSTEMS AND VACCINES
US6261573B1 (en) 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US6512102B1 (en) 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
WO2000042994A2 (en) 1999-01-21 2000-07-27 North Shore-Long Island Jewish Research Institute Inhibition of bacterial dissemination
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US20030170249A1 (en) 1999-02-19 2003-09-11 Hakomori Sen-Itiroh Vaccines directed to cancer-associated carbohydrate antigens
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
GB9906177D0 (en) 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
WO2000062066A1 (en) 1999-04-07 2000-10-19 Hitachi Chemical Co., Ltd. METHOD FOR JUDGING AUTOIMMUNE DISEASE, METHOD FOR DETECTING ANTI-Reg PROTEIN AUTOANTIBODY AND DIAGNOSTICS FOR AUTOIMMUNE DISEASES
BRPI0010612B8 (en) 1999-04-19 2021-05-25 Smithkline Beecham Biologicals S A vaccines
US6685699B1 (en) 1999-06-09 2004-02-03 Spectrx, Inc. Self-removing energy absorbing structure for thermal tissue ablation
AU6884200A (en) 1999-08-26 2001-03-19 Biovitrum Ab Novel response element
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US7084256B2 (en) 1999-09-24 2006-08-01 Large Scale Biology Corporation Self antigen vaccines for treating B cell lymphomas and other cancers
JP4162813B2 (en) 1999-10-28 2008-10-08 久光製薬株式会社 Iontophoresis device
US6218186B1 (en) 1999-11-12 2001-04-17 Trustees Of The University Of Pennsylvania HIV-MSCV hybrid viral vector for gene transfer
ES2370262T3 (en) 1999-11-15 2011-12-14 Oncothyreon Inc. LIPID ANALOGS TO SYNTHETICS AND THEIR USES.
US20020064801A1 (en) 1999-12-01 2002-05-30 Ryan Jeffrey R. Novel and practical serological assay for the clinical diagnosis of leishmaniasis
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US6587792B1 (en) 2000-01-11 2003-07-01 Richard A. Thomas Nuclear packing efficiency
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
AU2001233132A1 (en) 2000-01-31 2001-08-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Hybrid adeno-retroviral vector for the transfection of cells
EP1122542A1 (en) 2000-02-01 2001-08-08 Anda Biologicals S.A. Method for the rapid detection of whole microorganisms on retaining membranes by use of chaotropic agents
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
CN1606446A (en) 2000-05-19 2005-04-13 科里克萨有限公司 Method for preventing and treating communicable diseases and other diseases using monosaccharides and disaccharides
US7125549B2 (en) 2000-05-31 2006-10-24 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
DE10041515A1 (en) 2000-08-24 2002-03-14 Gerold Schuler Process for the production of ready-to-use, antigen-loaded or unloaded, cryopreserved mature dendritic cells
US6969704B1 (en) 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
US20020155997A1 (en) 2000-10-06 2002-10-24 Kurt Zimmermann Kyberdrug as autovaccines with immune-regulating effects
AU4433702A (en) 2000-10-18 2002-04-29 Smithkline Beecham Biolog Vaccines
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
EP1409533A2 (en) 2001-01-26 2004-04-21 Walter Reed Army Institute of Research Recombinant plasmodium falciparum merozoite protein-1/42 vaccine
US6893820B1 (en) 2001-01-31 2005-05-17 The Ohio State University Research Foundation Detection of methylated CpG rich sequences diagnostic for malignant cells
GB0105360D0 (en) 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
US7029685B2 (en) 2001-03-26 2006-04-18 The United States Of America As Represented By The Secretary Of The Army Plasmodium falciparum AMA-1 protein and uses thereof
EP1423405A4 (en) 2001-03-26 2005-01-05 Us Army Plasmodium falciparum ama-1 protein and uses thereof
US6933123B2 (en) 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
US6844192B2 (en) 2001-06-29 2005-01-18 Wake Forest University Adenovirus E4 protein variants for virus production
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
WO2003021227A2 (en) 2001-09-05 2003-03-13 The Children's Hospital Of Philadelphia Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US6752995B2 (en) 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
ATE457733T1 (en) 2002-05-09 2010-03-15 Oncothyreon Inc LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS
US7018345B2 (en) 2002-12-06 2006-03-28 Hisamitsu Pharmaceutical Co., Inc. Iontophoresis system
US20050123550A1 (en) 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
FR2857875A1 (en) 2003-07-25 2005-01-28 Univ Reims Champagne Ardenne Immunogenic composition containing fatty acid-modified peptides from protein P-170, useful e.g. for reversing multidrug resistance of cancer cells
US20050244419A1 (en) 2003-07-25 2005-11-03 Pierre-Francois Tosi Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
FR2862062B1 (en) 2003-11-06 2005-12-23 Oreal LIPID A AND TOPICAL COMPOSITION, IN PARTICULAR COSMETIC, COMPRISING IT
WO2006055729A1 (en) 2004-11-16 2006-05-26 Transcutaneous Technologies Inc. Iontophoretic device and method for administering immune response-enhancing agents and compositions
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2484375T1 (en) * 2006-09-26 2018-08-31 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CA2698668A1 (en) 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
WO2010141861A1 (en) * 2009-06-05 2010-12-09 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
CN103118678A (en) 2010-07-16 2013-05-22 约翰斯·霍普金斯大学 Methods and compositions for cancer immunotherapy
CN103347898B (en) * 2011-01-10 2017-12-05 Ct大西洋有限公司 Including the therapeutic alliance with tumor associated antigen binding antibody
JP2014510721A (en) * 2011-02-15 2014-05-01 イミューン デザイン コーポレイション Methods for enhancing immunogen-specific immune responses with vector vaccines
EP3563834A1 (en) 2012-02-07 2019-11-06 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
JP5328975B2 (en) 2012-12-19 2013-10-30 ルネサスエレクトロニクス株式会社 RF power module
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment

Also Published As

Publication number Publication date
EA201591786A1 (en) 2016-02-29
AU2014253791A1 (en) 2015-10-15
JP6712304B2 (en) 2020-06-17
CN105209047A (en) 2015-12-30
WO2014172637A1 (en) 2014-10-23
US20140328904A1 (en) 2014-11-06
AU2019210644A1 (en) 2019-08-22
EP2986303A1 (en) 2016-02-24
AU2014253791B2 (en) 2019-05-02
US20150352135A1 (en) 2015-12-10
MX370573B (en) 2019-12-17
US20150359811A1 (en) 2015-12-17
ZA201507278B (en) 2017-03-29
US8957047B2 (en) 2015-02-17
CA2909221A1 (en) 2014-10-23
KR102039520B1 (en) 2019-11-01
ZA201603332B (en) 2017-08-30
BR112015025709A2 (en) 2017-07-18
US20190269714A1 (en) 2019-09-05
EP2986303B1 (en) 2020-02-26
JP6426706B2 (en) 2018-11-21
JP2019031540A (en) 2019-02-28
MX2015014431A (en) 2016-06-02
CN105209047B (en) 2020-08-18
HK1214510A1 (en) 2016-07-29
US20140314834A1 (en) 2014-10-23
US10342815B2 (en) 2019-07-09
JP2016516824A (en) 2016-06-09
US8962593B2 (en) 2015-02-24
EA032326B1 (en) 2019-05-31
KR20160022808A (en) 2016-03-02
EP3711768A1 (en) 2020-09-23
US10993956B2 (en) 2021-05-04

Similar Documents

Publication Publication Date Title
ZA201603332B (en) Gla monotherapy for use in cancer treatment
EP2977018A4 (en) Treatment tool
IL251630A0 (en) Combination therapy for use in cancer therapy
EP2977019A4 (en) Treatment tool
HK1211982A1 (en) Cancer treatment
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
HK1198133A1 (en) Crizotinib for use in the treatment of cancer
IL244353A0 (en) Compounds and use for treating cancer
EP2982331A4 (en) Treatment tool
HK1215164A1 (en) Treatment methods
GB201304872D0 (en) Treatment
EP3733184C0 (en) Pyrimidine compounds for use in the treatment of cancer
GB201322386D0 (en) Straight in line
IL238453A0 (en) Trans-clomiphene for use in cancer therapy
HK1210023A1 (en) Cancer treatment
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
HK1216391A1 (en) Combination treatment
PL3071192T3 (en) Curcuphenol compound for use in treating cancer
GB201307310D0 (en) Treatment
GB201222563D0 (en) Cancer treatment
EP3104863C0 (en) Salicylates for use in the treatment of cancer
GB201314623D0 (en) Novel mucinase for use in therapy or prophylaxis
GB201322958D0 (en) Uses of oligouronates in cancer treatment
GB201300546D0 (en) Cancer Treatment
GB201321531D0 (en) Treatment for cancers